Loading clinical trials...
Loading clinical trials...
SPOTLIGHT 204: A Multicenter, Phase 2b, Open-label, Non-randomized, Clinical Trial to Evaluate Safety, Tolerability and Preliminary Efficacy of Intra-lesional BO-112 in Patients With Resectable Primary Low and High Risk Basal Cell Carcinoma
Conditions
Interventions
BO-112
Locations
10
Israel
Soroka Medical Center
Beersheba, Israel
Rambam Medical Center
Haifa, Israel
Hadassah Ein Kerem Medical Center
Jerusalem, Israel
Kaplan Medical Center
Rehovot, Israel
Hospital Clínic Barcelona
Barcelona, Spain
Hospital de Basurto
Bilbao, Spain
Start Date
May 27, 2024
Primary Completion Date
June 1, 2026
Completion Date
June 1, 2028
Last Updated
January 26, 2026
NCT03050268
NCT05969860
NCT05651828
NCT07144384
NCT07182240
NCT06623201
Lead Sponsor
Highlight Therapeutics
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions